|
|
||||||||
,1
,



* Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261;
Department of Kinesiology, University of Maryland, College Park, Maryland 20742;
Department of Physical Therapy, University of Maryland Eastern Shore, Princess Anne, Maryland 21853;
Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, Baltimore, Maryland 21224
| Abstract |
|---|
|
|
|---|
Key Words: GDF8 skeletal muscle transcription
Myostatin (growth and differentiation factor 8 [GDF8]) is a transforming growth factor-ß superfamily member with importance as a negative growth regulator for skeletal muscle, such that mutations in the myostatin gene result in a hypermuscular phenotype in mice and cattle (14). How myostatin influences muscle phenotypes is unclear. Higher levels of myostatin immunoreactivity have been reported in the muscle and serum of HIV-infected men with muscle wasting (5) and in the plasma of young men exposed to prolonged best rest (6). Reardon et al. (7) reported higher levels of myostatin mRNA in muscle samples from patients with chronic disuse atrophy associated with hip osteoarthritis compared with healthy control subjects. In rats, two reports have demonstrated that myostatin expression is reduced from elevated levels in response to reloading after atrophy-inducing conditions (8, 9). Thus, increases in myostatin expression have been observed in conditions associated with muscle atrophy, and myostatin expression appears to be responsive to muscle loading after atrophy.
In the present study, we sought to determine whether myostatin expression was altered by increased muscle loading in healthy individuals. Presumably, for muscle hypertrophy to occur in response to a stimulus, intrinsic regulators of muscle cell size must be altered in some way. To address this issue, we studied the response of myostatin expression in humans to heavy-resistance strength training (ST), which is associated with increases in muscle strength and mass (10, 11), and we hypothesized that ST would reduce myostatin expression.
The subjects studied consisted of properly consented young (2030 years old; 4 men, 4 women) and older (6575 years old; 3 men, 4 women) healthy, sedentary men and women. All subjects performed a 9-week unilateral heavy-resistance ST program as previously described in detail (12). Briefly, the training protocol consisted of unilateral ST of the dominant leg performed by the knee extensors using a Keiser K-300 pneumatic resistance machine 3 days per week. Each supervised ST session resulted in 50 completed repetitions performed at near maximal resistance, thus resulting in a highly strenuous muscle loading stimulus. Specified rest periods (90180 sec) were allowed between sets, and progressive increases in resistance occurred throughout the 9-week training program. All subjects were reminded throughout the study not to alter their regular activity levels or dietary habits for the duration of the investigation.
Both before and after ST, subjects completed tests aimed at characterizing muscle phenotypes. One repetition maximum (1RM) strength was measured as described in detail elsewhere (12) with standard techniques using the same Keiser equipment used for the strength training. Percentage of body fat was determined using dual-energy X-ray absorptiometry using standard techniques, and muscle volume of the quadriceps was measured using magnetic resonance imaging (MRI) as previously described (13). Briefly, the dominant thigh of each subject was scanned before and at least 48 hr after the last ST session to obtain axial slices of the quadriceps muscle group extending from the superior border of the patella to the anterior superior iliac spine. The cross-sectional area (CSA) of each quadriceps slice was determined from the images using NIH Image version 1.61 software and the quadriceps muscle volume was calculated. The details of the study design, as well as complete analyses of the response of muscle phenotypes to ST, have been previously published (1114).
Biopsies were obtained using standard needle biopsy techniques from the vastus lateralis muscle of the trained leg 2 weeks before ST and again 48 to 72 hr after the last ST session. Muscle samples were not available from the untrained leg. Total RNA was extracted from the samples using a standard phenol-based extraction method (Ambion, Austin, TX), quantified by determining absorbance at 260 nm in triplicate, treated with DNase I (Ambion), and reverse transcribed using the Reverse Transcription Reagents kit (Applied Biosystems, Foster City, CA) with random hexamers.
Myostatin expression was determined by quantitative, or real time, PCR (qPCR) using the ABI 7700 DNA Sequence Detection System (TaqMan; Applied Biosystems) using standard fluorescent chemistries and thermal cycling conditions as directed by the manufacturer. Primer and probe sequences were designed for myostatin mRNA (NM_005259) using Primer Express software (Applied Biosystems) as follows:
Forward primer: 5'-AGGTATACTGGAATCC GATCTCTGA-3'
Reverse primer: 5'-CACTGTCTTCACATCAAT GCTCTG-3'
Probe: 5'-CTTGACATGAACCCAGGCACTGG TATTTG-3'
Sequences were chosen to exclude known sites of sequence variability (15). The probe was labeled in the standard manner with FAM reporter (5') and TAMRA quencher (3') dyes. 18S rRNA was used as an internal expression control and was amplified using the Ribosomal RNA Control Reagents kit (Applied Biosystems). For each myostatin qPCR reaction, 14 ng of cDNA was added to optimized primer and probe concentrations, with 25 µl of PCR Master Mix. A corresponding well contained 7 ng of cDNA with reaction reagents for the qPCR of 18S rRNA. All reactions were performed in duplicate. Thermal cycling conditions were as specified by the manufacturer: 50°C for 2 min, 95°C for 10 min, and 40 cycles as follows: 95°C for 15 sec and ramp to 60°C for 1 min. Known concentration standards were developed using cDNA (obtained as outlined above) from a commercially available skeletal muscle total RNA source (Ambion), and optimization reactions were performed to ensure that all experimental samples fell within the range of the resulting standard curves. Standard curves were generated for both myostatin and 18S rRNA, and the CT (Cycle Threshold) value for each sample was then used to calculate relative expression based on the respective standard curve equation, according to the manufacturer's instructions. Myostatin expression level was normalized to the 18S rRNA control gene quantity after determining no change in 18S rRNA expression in response to ST.
One-way analysis of variance (ANOVA) with repeated measures was used to test for changes in myostatin expression in response to ST, with LSD post hoc analysis. Independent sample t tests were used to confirm no age and sex differences in myostatin expression, thus allowing the subjects to be pooled for statistical analysis. For the pooled samples, a paired-sample t test was used to test for ST-related (before versus after ST) changes in normalized myostatin expression. Analysis of non-normalized myostatin expression (e.g., without normalizing to 18S rRNA) revealed similar results (data not shown). Linear regression analysis was performed to determine potential associations of myostatin expression with muscle strength and mass phenotypes.
Subject characteristics are shown in Table I
. ST significantly reduced normalized myostatin expression by 37% (2.70 ± 0.36 vs 1.69 ± 0.18 U, arbitrary units; P < 0.05; Fig. 1
), but had no effect on 18S rRNA expression. ANOVA analysis revealed a significant change in myostatin expression in response to ST (P < 0.05), with no significant age or gender differences. Figure 1
shows the individual responses for each subject, demonstrating that the majority of individuals showed a reduction in myostatin expression, with no gender differences in the response. Subjects with lower baseline levels of myostatin were more likely to show little or no change in expression in response to ST. No significant relationships were observed between myostatin expression and muscle volume, strength, or body mass for either baseline expression or change in expression in response to ST.
|
|
Myostatin is well established as a negative regulator of muscle growth in animal models (16). The mechanism by which myostatin inhibits muscle growth is uncertain, although Carlson et al. (17) and others (18, 19) have suggested an inhibitory effect on skeletal muscle satellite cells. We pursued the present investigation with the hypothesis that myostatin mRNA levels would be reduced in response to a program of heavy-resistance ST designed to increase muscle mass and strength (i.e., inhibition of the growth inhibitor). Wehling et al. (8) demonstrated that periodic reloading of otherwise unloaded rat plantaris muscle resulted in less elevated myostatin levels (55% increase versus ambulatory controls) compared with a continuously unloaded condition (110% increase versus ambulatory controls). Moreover, Lalani et al. (9) reported increased myostatin mRNA and protein in several rat muscles in response to microgravity, and a normalization of those levels after the return to normal gravitation. Recent work by Kawada et al. (20) demonstrated that myostatin expression was significantly reduced upon reloading of hindlimb suspended muscle in mice, with no change in expression in response to either aging-related or unloading-induced atrophy. These data indicate that myostatin is responsive to muscle loading in some contexts, and thus might represent an important cell size regulator for skeletal muscle.
In the present study, the issue was whether myostatin expression was responsive to additional muscle loading in normal, ambulatory (although sedentary) individuals. As Lalani et al. (9) postulate, a homeostatic balance likely exists between positive (e.g., insulin-like growth factors) and negative (e.g., myostatin) growth regulators in skeletal muscle, thus providing for maintenance of muscle fiber size over moderate amounts of time. This balance would be expected to shift during loading or atrophy conditions, thus resulting in changes in muscle cell size. Our results indicate that heavy-resistance ST leads to a significant reduction in skeletal muscle myostatin expression in young and older men and women, with no age or gender differences. No significant correlations were observed with changes in muscle strength or volume, which is consistent with previous observations in animal models (8, 17). Future investigations will be required to verify and extend the findings of the present work.
In conclusion, ST significantly reduces skeletal muscle myostatin (GDF8) expression in sedentary, healthy men and women. These data provide evidence that myostatin is responsive to muscle loading in healthy adult humans, which may have relevance in future work where myostatin is studied as a therapeutic target for muscle wasting disorders.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 To whom requests for reprints should be addressed at Department of Kinesiology, University of Maryland, College Park, MD 20742. E-mail: sroth1{at}umd.edu ![]()
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. L. Allen, A. S. Cleary, K. J. Speaker, S. F. Lindsay, J. Uyenishi, J. M. Reed, M. C. Madden, and R. S. Mehan Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E918 - E927. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. Kollias and J. C. McDermott Transforming growth factor-{beta} and myostatin signaling in skeletal muscle J Appl Physiol, March 1, 2008; 104(3): 579 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-s. Kim, J. K. Petrella, J. M. Cross, and M. M. Bamman Load-mediated downregulation of myostatin mRNA is not sufficient to promote myofiber hypertrophy in humans: a cluster analysis J Appl Physiol, November 1, 2007; 103(5): 1488 - 1495. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Lewis, M. Fournier, T. W. Storer, S. Bhasin, J. Porszasz, S.-G. Ren, X. Da, and R. Casaburi Skeletal muscle adaptations to testosterone and resistance training in men with COPD J Appl Physiol, October 1, 2007; 103(4): 1299 - 1310. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. R. Harridge Plasticity of human skeletal muscle: gene expression to in vivo function Exp Physiol, September 1, 2007; 92(5): 783 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Heinemeier, J. L. Olesen, P. Schjerling, F. Haddad, H. Langberg, K. M. Baldwin, and M. Kjaer Short-term strength training and the expression of myostatin and IGF-I isoforms in rat muscle and tendon: differential effects of specific contraction types J Appl Physiol, February 1, 2007; 102(2): 573 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kvorning, M. Andersen, K. Brixen, P. Schjerling, C. Suetta, and K. Madsen Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humans J. Physiol., January 15, 2007; 578(2): 579 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Matsakas, C. Bozzo, N. Cacciani, F. Caliaro, C. Reggiani, F. Mascarello, and M. Patruno Effect of swimming on myostatin expression in white and red gastrocnemius muscle and in cardiac muscle of rats Exp Physiol, November 1, 2006; 91(6): 983 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lopez-Soriano, C. Chiellini, M. Maffei, P. A. Grimaldi, and J. M. Argiles Roles of Skeletal Muscle and Peroxisome Proliferator-Activated Receptors in the Development and Treatment of Obesity Endocr. Rev., May 1, 2006; 27(3): 318 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. G. Coffey, A. Shield, B. J. Canny, K. A. Carey, D. Cameron-Smith, and J. A. Hawley Interaction of contractile activity and training history on mRNA abundance in skeletal muscle from trained athletes Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E849 - E855. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Huygens, M. A. I. Thomis, M. W. Peeters, J. Aerssens, R. Vlietinck, and G. P. Beunen Quantitative trait loci for human muscle strength: linkage analysis of myostatin pathway genes Physiol Genomics, August 11, 2005; 22(3): 390 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. I. Martin and I. A. Johnston The role of myostatin and the calcineurin-signalling pathway in regulating muscle mass in response to exercise training in the rainbow trout Oncorhynchus mykiss Walbaum J. Exp. Biol., June 1, 2005; 208(11): 2083 - 2090. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-s. Kim, J. M. Cross, and M. M. Bamman Impact of resistance loading on myostatin expression and cell cycle regulation in young and older men and women Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1110 - E1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Salerno, M. Thomas, D. Forbes, T. Watson, R. Kambadur, and M. Sharma Molecular analysis of fiber type-specific expression of murine myostatin promoter Am J Physiol Cell Physiol, October 1, 2004; 287(4): C1031 - C1040. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |